Emerging potential of parenteral estrogen as androgen deprivation therapy for prostate cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
Emerging potential of parenteral estrogen as androgen deprivation therapy for prostate cancer ; volume:04 ; number:02 ; year:2015 ; pages:095-097
South Asian journal of cancer ; 04, Heft 02 (2015), 095-097
- Contributor
-
Ali Shah, Syed Imran
- DOI
-
10.4103/2278-330X.155699
- URN
-
urn:nbn:de:101:1-2021022619364591037730
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:23 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Ali Shah, Syed Imran
Other Objects (12)
Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer
Adaptive phenotype drives resistance to androgen deprivation therapy in prostate cancer
Androgen deprivation restores ARHGEF2 to promote neuroendocrine differentiation of prostate cancer
Androgen deprivation in prostate cancer: benefits of home-based resistance training
Correction: Androgen deprivation restores ARHGEF2 to promote neuroendocrine differentiation of prostate cancer
Vascular responses to radiotherapy and androgen-deprivation therapy in experimental prostate cancer
Radiotherapy with or without androgen deprivation therapy in intermediate risk prostate cancer?
Discovery of prostate specific antigen pattern to predict castration resistant prostate cancer of androgen deprivation therapy
An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer
Bone mineral density in Jamaican men on androgen deprivation therapy for prostate cancer
PTP1B regulates lymphocytes responses androgen deprivation
Docetaxel in the management of PSA progression following primary androgen deprivation for prostate cancer
Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer
Adaptive phenotype drives resistance to androgen deprivation therapy in prostate cancer
Androgen deprivation restores ARHGEF2 to promote neuroendocrine differentiation of prostate cancer
Androgen deprivation in prostate cancer: benefits of home-based resistance training
Correction: Androgen deprivation restores ARHGEF2 to promote neuroendocrine differentiation of prostate cancer
Vascular responses to radiotherapy and androgen-deprivation therapy in experimental prostate cancer
Radiotherapy with or without androgen deprivation therapy in intermediate risk prostate cancer?
Discovery of prostate specific antigen pattern to predict castration resistant prostate cancer of androgen deprivation therapy
An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer
Bone mineral density in Jamaican men on androgen deprivation therapy for prostate cancer
PTP1B regulates lymphocytes responses androgen deprivation
Docetaxel in the management of PSA progression following primary androgen deprivation for prostate cancer
Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer
Adaptive phenotype drives resistance to androgen deprivation therapy in prostate cancer
Androgen deprivation restores ARHGEF2 to promote neuroendocrine differentiation of prostate cancer
Androgen deprivation in prostate cancer: benefits of home-based resistance training
Correction: Androgen deprivation restores ARHGEF2 to promote neuroendocrine differentiation of prostate cancer
Vascular responses to radiotherapy and androgen-deprivation therapy in experimental prostate cancer
Radiotherapy with or without androgen deprivation therapy in intermediate risk prostate cancer?
Discovery of prostate specific antigen pattern to predict castration resistant prostate cancer of androgen deprivation therapy
An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer
Bone mineral density in Jamaican men on androgen deprivation therapy for prostate cancer
PTP1B regulates lymphocytes responses androgen deprivation